文献速递肝病消化道肿瘤与早癌

谷氨酰胺代谢竞争驱动肿瘤内GPR109A+髓系细胞免疫抑制重编程促进肝癌进展

Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+ myeloid cells to promote liver cancer progression.
PubMed 文献 · Gut · 2025-01-17

该研究利用人样本、多种小鼠模型、GPR109A敲除小鼠、免疫细胞清除及原代细胞共培养,发现肝癌微环境谷氨酰胺缺乏驱动免疫抑制性GPR109A+髓系细胞浸润导致免疫逃逸;阻断GPR109A可减少G-MDSCs和M2样TAMs并增强CD8+ T细胞抗肿瘤反应及免疫治疗疗效;机制上肿瘤细胞与髓系细胞通过SLC1A5竞争谷氨酰胺摄取,经IRE1α/XBP1通路诱导GPR109A表达。

要点

  • 肝癌微环境谷氨酰胺缺乏驱动GPR109A+髓系细胞浸润并抑制抗肿瘤免疫。
  • 阻断GPR109A减少G-MDSCs和M2样TAMs,增强CD8+ T细胞反应及免疫治疗疗效。
  • 限制肿瘤细胞谷氨酰胺摄取、阻断IRE1α/XBP1或补充谷氨酰胺可消除免疫抑制并减缓肿瘤进展。

核心结论

  • 肝癌细胞与髓系细胞间的免疫代谢串扰通过谷氨酰胺代谢/内质网应激/GPR109A轴促进肿瘤进展,提示GPR109A可作为免疫代谢检查点和潜在治疗靶点。

研究设计与样本

  • 研究采用人样本和多种小鼠模型评估GPR109A与肝癌进展的相关性。
  • 使用GPR109A敲除小鼠、免疫细胞清除和原代细胞共培养模型确定GPR109A对肿瘤微环境的调控并鉴定肿瘤内GPR109A+髓系细胞形成的机制。

主要发现

  • 肝癌肿瘤微环境谷氨酰胺缺乏驱动免疫抑制性GPR109A+髓系细胞浸润,导致免疫监视逃逸。
  • 阻断GPR109A减少G-MDSCs和M2样TAMs丰度,触发CD8+ T细胞抗肿瘤反应并改善肝癌免疫治疗疗效。
  • 肿瘤细胞与肿瘤浸润髓系细胞通过转运体SLC1A5竞争谷氨酰胺摄取以调控抗肿瘤免疫。
  • 谷氨酰胺竞争破坏内质网稳态并诱导髓系细胞未折叠蛋白反应,通过IRE1α/XBP1通路促进GPR109A表达。
  • 限制肝癌细胞谷氨酰胺摄取、阻断IRE1α/XBP1信号或补充谷氨酰胺可消除GPR109A+髓系细胞的免疫抑制作用并减缓肿瘤进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The metabolic characteristics of liver cancer drive considerable hurdles to immune cells function and cancer immunotherapy. However, how metabolic reprograming in the tumour microenvironment impairs the antitumour immune response remains unclear. DESIGN: Human samples and multiple murine models were employed to evaluate the correlation between GPR109A and liver cancer progression. GPR109A knockout mice, immune cells depletion and primary cell coculture models were used to determine the regulation of GPR109A on tumour microenvironment and identify the underlying mechanism responsible for the formation of intratumour GPR109A+myeloid cells. RESULTS: We demonstrate that glutamine shortage in liver cancer tumour microenvironment drives an immunosuppressive GPR109A+myeloid cells infiltration, leading to the evasion of immune surveillance. Blockade of GPR109A decreases G-MDSCs and M2-like TAMs abundance to trigger the antitumour responses of CD8+ T cells and further improves the immunotherapy efficacy against liver cancer. Mechanistically, tumour cells and tumour-infiltrated myeloid cells compete for glutamine uptake via the transporter SLC1A5 to control antitumour immunity, which disrupts the endoplasmic reticulum (ER) homoeostasis and induces unfolded protein response of myeloid cells to promote GPR109A expression through IRE1α/XBP1 pathway. The restriction of glutamine uptake in liver cancer cells, as well as the blockade of IRE1α/XBP1 signalling or glutamine supplementation, can eliminate the immunosuppressive effects of GPR109A+ myeloid cells and slow down tumour progression. CONCLUSION: Our findings identify the immunometabolic crosstalk between liver cancer cells and myeloid cells facilitates tumour progression via a glutamine metabolism/ER stress/GPR109A axis, suggesting that GPR109A can be exploited as an immunometabolic checkpoint and putative target for cancer treatment.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Yang Y, Pei T, Liu C, et al. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+ myeloid cells to promote liver cancer progression. Gut. 2025. PMID: 38981667. doi:10.1136/gutjnl-2024-332429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。